These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 37645755)

  • 1. Adipose-Tumor Crosstalk contributes to CXCL5 Mediated Immune Evasion in PDAC.
    Walsh RM; Ambrose J; Jack JL; Eades AE; Bye B; Ruckert MT; Olou AA; Messaggio F; Chalise P; Pei D; VanSaun MN
    bioRxiv; 2023 Aug; ():. PubMed ID: 37645755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma.
    Fitzgerald AA; Wang S; Agarwal V; Marcisak EF; Zuo A; Jablonski SA; Loth M; Fertig EJ; MacDougall J; Zhukovsky E; Trivedi S; Bhatia D; O'Neill V; Weiner LM
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34737215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
    J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression and role of the immune checkpoint regulator PD-L1 in the tumor-stroma interplay of pancreatic ductal adenocarcinoma.
    Daunke T; Beckinger S; Rahn S; Krüger S; Heckl S; Schäfer H; Wesch D; Pilarsky C; Eckstein M; Hartmann A; Röcken C; Wandmacher AM; Sebens S
    Front Immunol; 2023; 14():1157397. PubMed ID: 37449210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CXCL5 overexpression predicts a poor prognosis in pancreatic ductal adenocarcinoma and is correlated with immune cell infiltration.
    Zhang R; Liu Q; Peng J; Wang M; Li T; Liu J; Cui M; Zhang X; Gao X; Liao Q; Zhao Y
    J Cancer; 2020; 11(9):2371-2381. PubMed ID: 32201508
    [No Abstract]   [Full Text] [Related]  

  • 6. Combination of PD-1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer.
    Ma Y; Li J; Wang H; Chiu Y; Kingsley CV; Fry D; Delaney SN; Wei SC; Zhang J; Maitra A; Yee C
    Gastroenterology; 2020 Jul; 159(1):306-319.e12. PubMed ID: 32179091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CRISPR/Cas9-mediated deletion of Interleukin-30 suppresses IGF1 and CXCL5 and boosts SOCS3 reducing prostate cancer growth and mortality.
    Sorrentino C; D'Antonio L; Ciummo SL; Fieni C; Landuzzi L; Ruzzi F; Vespa S; Lanuti P; Lotti LV; Lollini PL; Di Carlo E
    J Hematol Oncol; 2022 Oct; 15(1):145. PubMed ID: 36224639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD40L-armed oncolytic herpes simplex virus suppresses pancreatic ductal adenocarcinoma by facilitating the tumor microenvironment favorable to cytotoxic T cell response in the syngeneic mouse model.
    Wang R; Chen J; Wang W; Zhao Z; Wang H; Liu S; Li F; Wan Y; Yin J; Wang R; Li Y; Zhang C; Zhang H; Cao Y
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35086948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response to immune checkpoint blockade improved in pre-clinical model of breast cancer after bariatric surgery.
    Sipe LM; Chaib M; Korba EB; Jo H; Lovely MC; Counts BR; Tanveer U; Holt JR; Clements JC; John NA; Daria D; Marion TN; Bohm MS; Sekhri R; Pingili AK; Teng B; Carson JA; Hayes DN; Davis MJ; Cook KL; Pierre JF; Makowski L
    Elife; 2022 Jul; 11():. PubMed ID: 35775614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Obesity diminishes response to PD-1-based immunotherapies in renal cancer.
    Boi SK; Orlandella RM; Gibson JT; Turbitt WJ; Wald G; Thomas L; Buchta Rosean C; Norris KE; Bing M; Bertrand L; Gross BP; Makkouk A; Starenki D; Farag KI; Sorge RE; Brown JA; Gordetsky J; Yasin H; Garje R; Nandagopal L; Weiner GJ; Lubaroff DM; Arend RC; Li P; Zakharia Y; Yang E; Salem AK; Nepple K; Marquez-Lago TT; Norian LA
    J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33427691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TGFβ-derived immune modulatory vaccine: targeting the immunosuppressive and fibrotic tumor microenvironment in a murine model of pancreatic cancer.
    Perez-Penco M; Weis-Banke SE; Schina A; Siersbæk M; Hübbe ML; Jørgensen MA; Lecoq I; Lara de la Torre L; Bendtsen SK; Martinenaite E; Holmström MO; Madsen DH; Donia M; Ødum N; Grøntved L; Andersen MH
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36600556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Murine- and Human-Derived Autologous Organoid/Immune Cell Co-Cultures as Pre-Clinical Models of Pancreatic Ductal Adenocarcinoma.
    Holokai L; Chakrabarti J; Lundy J; Croagh D; Adhikary P; Richards SS; Woodson C; Steele N; Kuester R; Scott A; Khreiss M; Frankel T; Merchant J; Jenkins BJ; Wang J; Shroff RT; Ahmad SA; Zavros Y
    Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33348809
    [No Abstract]   [Full Text] [Related]  

  • 13. Combined Autophagy Inhibition and Dendritic Cell Recruitment Induces Antitumor Immunity and Enhances Immune Checkpoint Blockade Sensitivity in Pancreatic Cancer.
    Oyama K; Nakata K; Tsutsumi C; Hayashi M; Zhang B; Mochida Y; Shinkawa T; Hirotaka K; Zhong P; Date S; Luo H; Kubo A; Higashijima N; Yamada Y; Abe T; Ideno N; Koikawa K; Iwamoto C; Ikenaga N; Ohuchida K; Onishi H; Morisaki T; Kuba K; Oda Y; Nakamura M
    Cancer Res; 2024 Dec; 84(24):4214-4232. PubMed ID: 39288081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncolytic virus-mediated reducing of myeloid-derived suppressor cells enhances the efficacy of PD-L1 blockade in gemcitabine-resistant pancreatic cancer.
    Kajiwara Y; Tazawa H; Yamada M; Kanaya N; Fushimi T; Kikuchi S; Kuroda S; Ohara T; Noma K; Yoshida R; Umeda Y; Urata Y; Kagawa S; Fujiwara T
    Cancer Immunol Immunother; 2023 May; 72(5):1285-1300. PubMed ID: 36436021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
    Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pancreatic Ductal Adenocarcinoma (PDAC) circulating tumor cells influence myeloid cell differentiation to support their survival and immunoresistance in portal vein circulation.
    Arnoletti JP; Reza J; Rosales A; Monreal A; Fanaian N; Whisner S; Srivastava M; Rivera-Otero J; Yu G; Phanstiel Iv O; Altomare DA; Tran Q; Litherland SA
    PLoS One; 2022; 17(3):e0265725. PubMed ID: 35316296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gut-derived lipopolysaccharide remodels tumoral microenvironment and synergizes with PD-L1 checkpoint blockade via TLR4/MyD88/AKT/NF-κB pathway in pancreatic cancer.
    Yin H; Pu N; Chen Q; Zhang J; Zhao G; Xu X; Wang D; Kuang T; Jin D; Lou W; Wu W
    Cell Death Dis; 2021 Oct; 12(11):1033. PubMed ID: 34718325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regnase-1 downregulation promotes pancreatic cancer through myeloid-derived suppressor cell-mediated evasion of anticancer immunity.
    Okabe J; Kodama T; Sato Y; Shigeno S; Matsumae T; Daiku K; Sato K; Yoshioka T; Shigekawa M; Higashiguchi M; Kobayashi S; Hikita H; Tatsumi T; Okamoto T; Satoh T; Eguchi H; Akira S; Takehara T
    J Exp Clin Cancer Res; 2023 Oct; 42(1):262. PubMed ID: 37814340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer.
    Mace TA; Shakya R; Pitarresi JR; Swanson B; McQuinn CW; Loftus S; Nordquist E; Cruz-Monserrate Z; Yu L; Young G; Zhong X; Zimmers TA; Ostrowski MC; Ludwig T; Bloomston M; Bekaii-Saab T; Lesinski GB
    Gut; 2018 Feb; 67(2):320-332. PubMed ID: 27797936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.